UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Rapid and Sustained Long- Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin- Associated Periodic Syndrome Ages Five Years and Younger

Brogan, PA; Hofer, M; Kuemmerle-Deschner, JB; Koné-Paut, I; Roesler, J; Kallinich, T; Horneff, G; ... Laxer, RM; + view all (2019) Rapid and Sustained Long- Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin- Associated Periodic Syndrome Ages Five Years and Younger. Arthritis & Rheumatology , 71 (11) pp. 1955-1963. 10.1002/art.41004. Green open access

[thumbnail of Brogan_et_al-2019-Arthritis_&_Rheumatology.pdf]
Preview
Text
Brogan_et_al-2019-Arthritis_&_Rheumatology.pdf - Published Version

Download (517kB) | Preview

Abstract

OBJECTIVE: To assess longer-term efficacy and safety of canakinumab and the response to vaccination in children aged ≤5 years with cryopyrin-associated periodic syndrome (CAPS). METHODS: CAPS patients (aged ≤5 years) received 2mg/kg canakinumab subcutaneously every 8 weeks; patients with neonatal onset multisystem inflammatory disease (NOMID), received a starting dose of 4 mg/kg in this open-label trial. Efficacy was evaluated using physician's global assessment (PGA), and serum levels of C-reactive protein (CRP) and amyloid A (SAA). Adverse events (AEs) were collected. Vaccination response was evaluated using post-vaccination antibody titers at 4 and 8 weeks after immunization. RESULTS: Of the 17 patients enrolled, 12 (71%) had Muckle-Wells syndrome, 4 (24%) had NOMID, and 1 (6%) had familial cold autoinflammatory syndrome. All patients (17/17) were complete responders to canakinumab. PGA improved, and 65% of patients had absent auto-inflammatory disease at the end of study. Median CRP levels decreased over time. No such change was evident in SAA levels. During the extension study, post-vaccination antibody titers increased above protective levels in 16/17 (94%) assessable vaccinations. Ten (59%) patients had AEs suspected to be related to canakinumab; 8 (47%) experienced at least 1 serious AE. None of the AEs/SAEs required interruption of canakinumab therapy. CONCLUSION: Canakinumab effectively maintained efficacy through 152 weeks and appears to have no effect on the ability to produce antibodies against standard childhood killed vaccines. Safety profile of canakinumab was consistent with previous studies, supporting long-term use of canakinumab for CAPS in children < 5 years of age. This article is protected by copyright. All rights reserved.

Type: Article
Title: Rapid and Sustained Long- Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin- Associated Periodic Syndrome Ages Five Years and Younger
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/art.41004
Publisher version: https://doi.org/10.1002/art.41004
Language: English
Additional information: © 2019 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/10076273
Downloads since deposit
41Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item